Indication

For the treatment of neovascular (wet) age-related macular degeneration (wAMD).

Medicine details

Medicine name:
brolucizumab (Beovu)
SMC ID:
SMC2272
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Eye
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC